• November 6, 2026



Choice Institutional Equities is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated November 05, 2026.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Wheaton Precious Metals revenue jumps 62% as record year-to-date performance builds

Related Posts

Bitcoin ETFs Snap Two-Week Losing Streak Despite Late-Week Slide

By  

Gen Z traders lean into ETFs as risk appetite cools: Binance Research

By  

SBI, Bank of Baroda eye first dollar bonds since RBI subsidy, sources say

By  

Beginner’s guide to SIP investing in passive mutual funds

By